Beijing Boao Jingdian Biotechnology
No. 3766 Nan Huan Rd, 8/F New Century Tower, Binjiang Dist., Beijing, Beijing Shi, 100000, China
Overview
CapitalBio Technology is an industry-leading life science company that develops and commercializes total health-care solutions. Their company provides a comprehensive portfolio of top-quality products to a diverse customer base ranging from biomedical researchers to healthcare professionals. Their products include an innovative and broad spectrum of microarray and microfluidic chips and related instruments, software and databases, reagents and consumables for basic and translational research, drug development, clinical diagnostics, biosafety and food safety, and molecular breeding. As a core subsidiary of CapitalBio Corporation and the Biological Chip Beijing National Engineering Research Center, CapitalBio Technology was registered in August 2012 and is headquartered in Economic-Technological Development Area in Beijing. CapitalBio Technology is a leading life science company that develops and commercializes total health-care solutions. With more than 35,000 square meters of office space, CapitalBio Technology employs more than 500 employees; 86 percent of these employees have at least Bachelor-level degrees, 14 of which are doctors or post-doctorates.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 1
Sector focus
- AgTech
- Biotechnology
- Health Care
- Life Science
Investment portfolio
- CapitalBio Technology
Participated · Equity · Jun 2020
Beijing博奥晶典生物技术有限公司 is a leading domestic provider of gene testing and biochip-based diagnostics with R&D, production, sales and a nationwide third‑party independent medical laboratory service. The company supplies technology and solutions to life sciences research, medical testing, new drug R&D, health management, forensic testing, agriculture/food safety and related fields. It claims the world’s largest original biochip technology platform, has drafted national standards, and holds more than 300 granted patents with a patent conversion rate near 50%. After completing a Pre-IPO financing of over ¥800 million, the company plans to accelerate new product R&D and expand its chip production lines. Management also intends to strengthen sales, marketing and overseas expansion. In addition, the company will initiate share‑reform work and prepare a科创板 (SSE STAR Market) IPO filing.
Team
Xing Wanli
President